Olema Pharmaceuticals, Inc. OLMA 深 沪
等待开盘 02-14 09:30:00 美东时间
23.78
+0.030
+0.13%
华盛通- 最 高29.50
- 今 开23.66
- 成交量 13.86万股
- 最 低 22.40
- 昨 收 23.75
- 总市值 95.96万
- 52周最高 36.2591
- 市盈率 静 --
- 换手率 343.36%
- 52周最低 2.86
- 委 比 42.49%
- 总股本 4.04万
- 历史最高 60.27
- 量 比 0.50
- 振 幅 29.89%
- 历史最低 1.10
- 每 手 1
- 风险率 9.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Olema Pharmaceuticals COO, CFO Shane Kovacs Departing, Effective Immediately
Olema Pharmaceuticals, Inc. (("Olema", or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast
01-31 05:02
Nasdaq Down 1%; Medtronic Earnings Top Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
2025-11-19 01:53
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.
2025-11-19 01:01
Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling more th...
2025-11-18 22:55
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals granted stock options to 11 new employees for 322,000 shares, effective June 2, 2025, under the 2022 Inducement Plan. The options vest over four years with an exercise price of $4.38 per share, in line with Nasdaq rules.
2025-06-03 20:30
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting
Olema Pharmaceutical announced the selection of a 90 mg dose for palazestrant in Phase 3 trials for ER+/HER2- metastatic breast cancer, with updates to be presented at the ASCO Annual Meeting.
2025-05-28 11:00
HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $30 price target.
2025-03-12 01:11
